AZURE
Clinical Trial Program
A prospective, randomized, open label, clinical trial to determine whether adjuvant treatment with zoledronic acid with (neo)adjuvant chemotherapy and/or (neo)adjuvant endocrine therapy is superior to standard therapy alone in improving the disease-free and bone metastasis-free survival of breast cancer patients. |
Phase III
Status
Finished
Tumour subtype:
HER2+, HR+, TNBC
Scenario
Adjuvant
SPONSOR
COLLABORATORS
PRINCIPAL INVESTIGATORS
Professor R Coleman, PhD (Cancer Research Centre, Weston Park Hospital Sheffield)
Sites
CLÍNICA UNIVERSITARIA DE NAVARRA, HOSPITAL CLÍNICO UNIV. LOZANO BLESA, HOSPITAL CLÍNICO UNIVERSITARIO DE VALENCIA, HOSPITAL SON LLATZER, HOSPITAL UNIVERSITARI VALL D’HEBRON, HOSPITAL UNIVERSITARIO 12 DE OCTUBRE, ICO GIRONA (HOSPITAL DR. JOSEP TRUETA), ICO HOSPITALET (DURAN I REYNALS), IPO COIMBRA (INSTITUTO PORTUGUÊS DE ONCOLOGIA DE COIMBRA FRANCISCO GENTIL, EPE)
